Holen Sie sich die Stockscreener-App
20.52
1.39%
-0.29
Handel nachbörslich:
21.22
0.70
+3.41%
Schlusskurs vom Vortag:
$20.81
Offen:
$21.09
24-Stunden-Volumen:
1.10M
Relative Volume:
0.57
Marktkapitalisierung:
$1.82B
Einnahmen:
$217.42M
Nettoeinkommen (Verlust:
$-243.25M
KGV:
-7.3412
EPS:
-2.7952
Netto-Cashflow:
$-278.35M
1W Leistung:
-7.94%
1M Leistung:
-3.71%
6M Leistung:
-3.71%
1J Leistung:
+113.08%
1-Tages-Spanne:
$20.50
$21.57
1-Wochen-Bereich:
$20.50
$22.74
52-Wochen-Spanne:
$9.42
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
20.52 | 1.84B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals Inc (SNDX) Cash Flow - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Syndax Pharmaceuticals (SNDX) Projected to Announce Quarterly Earnings on Monday - MarketBeat
Orbimed Advisors LLC Invests $22.48 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX|Syndax Pharmaceuticals Inc|Price:20.810|Chg%:-0.400 - TradingKey
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Granahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Price to sales forward of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView
Syndax Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SNDX - TradingView
Syndax Pharmaceuticals Inc. (SNDX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst - The Globe and Mail
Syndax Pharmaceuticals (SNDX) FDA Announcement Summary - Quartr
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Syndax Pharmaceuticals Inc. (SNDX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know - Yahoo! Finance Canada
Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - Sahm
SNDX Stock Price, Quote & Chart - ChartMill
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating - Moomoo
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Syndax Showcases Late-Stage Pipeline, Expands R&D Strategy - TipRanks
SNDX6417984 Bond Coupon Profile — Rate & Payments - TradingView
Syndax Pharmaceuticals Inc to Host R&D Day Transcript - GuruFocus
SNDX6417984 Bond Profile — Key Metrics - TradingView
A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push - MarketBeat
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead TherapiesSlideshow (NASDAQ:SNDX) 2026-07-14 - Seeking Alpha
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo! Finance Canada
SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027 - TradingView
Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts - Stock Titan
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - The Manila Times
Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo
Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan
Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Metzger Michael A - Moomoo
Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com - Investing.com Nigeria
SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan
Syndax Pharmaceuticals (SNDX) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):